Abstract:BACKGROUND:Numerous studies have shown that reducing the level of tumor necrosis factor-alpha (TNFα) through the use of anti-TNF antibodies or soluble TNF receptor is a safe and efficacious treatment to inflammatory diseases such as rheumatoid arthritis. Therefore, novel approaches to achieve this outcome are desired. The aim of this study was to investigate the characterization of a small molecule inhibitor, Y316, which blocks TNF mRNA upregulation and TNF production by lipopolysaccharides (LPS) stimulated monocytes.METHODS:Peripheral blood mononuclear cells (PBMC) from healthy volunteers were plated in 24-well plates and stimulated with LPS (1 µg/ml), phorbol-12-myristate-13-acetate (PMA) (100 ng/ml), zymosan (10 µg/ml) and Tsst (100 ng/ml). Supernatants were collected after 4-hour culture at 37°C, and quantitative determination of TNFα, interleukin-1β (IL-1β), IL-6, IL-8, IL-10 and IL-2 production in the supernatants was performed by colorimetric enzyme-linked immunosorbent assay (ELISA). Total RNA of PBMC was isolated and cytokine mRNA quantitation was performed by using a RNA level measuring kit (R & D Systems). PBMC were pretreated with Y316 (10 µmol/L, 1 µmol/L, 0.1 µmol/L, 0.01 µol/L and 0.001 µmol/L) or dimethyl sulfoxide at 37°C for 10 minutes, and then stimulated with LPS or PMA, protein concentrations of p44.42, IKBα, P38 and Jun NH2-terminal kinase were determined by Western blotting. Cyclic adenosine-3',5'-monophosphate (cAMP) of PBMC was measured by enzyme immunoassay kit (Amersham Pharmacia Biotech).RESULTS:Y316 blocked TNF production and inhibited the upregulation of TNF mRNA levels in response to LPS, and also prevented the production of IL-1 and IL-6. In contrast, Y316 augmented the production of IL-10 in LPS-stimulated monocytes. Y316 failed to prevent the production of IL-2 and TNF in antigen-stimulated T cells, suggesting that its effects may be cell-type specific. Y316 prevented the phosphorylation and activation of the MAPK, ERK, and therefore appeared to mediate its effects on TNF by acting at an early point in the signaling cascade induced in response to LPS. There was no effect of Y316 on cAMP levels either alone or in the presence of LPS.CONCLUSIONS:Y316 appears to be a small molecule inhibiting TNF production, which may act via a novel mechanism. Identification of the target of Y316 may lead to the development of alternative strategies for achieving selective cytokine inhibition.

The Protective Antibodies Induced by a Novel Epitope of Human TNF-α Could Suppress the Development of Collagen-Induced Arthritis

A Rationally Designed TNF-α Epitope-Scaffold Immunogen Induces Sustained Antibody Response and Alleviates Collagen-Induced Arthritis in Mice.

A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody As Scaffolds to Display Antagonistic Peptides

Targeting TNF-α with a tetravalent mini-antibody TNF-TeAb

A Novel Fusion Protein Attenuates Collagen-Induced Arthritis by Targeting Interleukin 17A and Tumor Necrosis Factor Alpha

Novel peptide inhibitor of human tumor necrosis factor-α has antiarthritic activity

Therapeutic effects of a novel tylophorine analog, NK-007, on collagen-induced arthritis through suppressing tumor necrosis factor α production and Th17 cell differentiation.

A Novel Human Scfv Fragment Against Tnf-Alpha from De Novo Design Method

Preparation and identification of transmembrane TNF-α(TM-TNF-α)specific monoclonal antibody

Development of a Recombinant Xenogeneic Tumor Necrosis Factor Alpha Protein Vaccine to Protect Mice from Experimental Colitis.

Effects Of A Novel Tylophorine Analog On Collagen-Induced Arthritis Through Inhibition Of The Innate Immune Response

A Synthetic Peptide Derived from A1 Module in CRD4 of Human TNF Receptor-1 Inhibits Binding and Proinflammatory Effect of Human TNF-α

Protective Effects of Overexpression TCR Vbeta5.2-HSP70 and TCR Vbeta8.2-HSP70 Against Collagen-Induced Arthritis in Rats.

Trivalent Soluble TNF Receptor, a Potent TNF-α Antagonist for the Treatment Collagen-Induced Arthritis.

Preparation and Characterization of a Fully Human Monoclonal Antibody Specific for Human Tumor Necrosis Factor Alpha

Discovery of Cyclic Peptide Inhibitors Targeted on TNFα-TNFR1 from Computational Design and Bioactivity Verification

Overexpression, Effective Renaturation, and Bioactivity of Novel Single-Chain Antibodies Against TNF-α

Therapeutic role of a vaccine targeting RANKL and TNF-α on collagen-induced arthritis.

A Novel BLyS Peptibody Down-Regulates B Cell and T Helper Cell Subsets in Vivo and Ameliorates Collagen-Induced Arthritis.

Retraction Note To: Structure-based Development and Optimization of Therapy Antibody Drugs Against TNFα

Characterization of A Small Molecule Inhibitor of Tumor Necrosis Factor-Alpha Production